Advanced Chemical Industries Limited

1st Quarter Report 2014

for the period of three months ended on 31 March 2014

Advanced Chemical Industries Limited <u>Statement of Financial Position</u> <u>As at 31 March 2014</u> <u>Unaudited</u>

	Note	31-Mar-2014 Taka	31-Dec-2013 Taka
<u>Assets</u>			
Property, plant and equipment:			
At cost / revaluation		3,507,451	3,423,342
Accumulated depreciation		(682,684)	(624,110
	2	2,824,767	2,799,232
Capital work-in-progress		538,586	585,257
Intangible assets		1,312	1,359
Long term investment	3	1,842,562	1,846,292
Total non-current assets		5,207,227	5,232,140
Current assets:			
Inventories	4	2,579,457	2,553,331
Trade receivables	5	1,546,288	1,576,569
Other receivables		111,766	146,161
Advance, deposits & prepayments	6	481,131	371,619
Advance income tax		407,703	350,014
Inter-company receivable	7	4,382,748	4,077,096
Cash and cash equivalents		303,351	250,325
		9,812,444	9,325,115
Total assets		15,019,671	14,557,255
Equity and liabilities			
Shareowners' equity:		·	
Share capital		286,618	285,821
Share premium		351,231	333,302
Capital reserve		1,671	1,671
Revaluation surplus		892,464	892,464
Available for sale reserve		107,973	111,330
Retained earnings		4,199,323	4,012,664
Current liabilities:		5,839,280	5,637,252
Bank overdraft		614,620	607,565
Short term bank loan		4,774,993	4,677,922
Long term loan- current portion		363,833	381,080
Trade payables		480,446	448,789
Other payables	8	1,223,867	1,017,887
Inter-company payables	9	479,572	364,071
Current portion of lease obligation	J	923	888
Current tax liability		548,978	466,635
		8,487,232	7,964,837
Long term liabilities	10	693,159	955,166
Total equity and liabilities	-	15,019,671	14,557,255
		\sim	

til &

Dr. Arif Dowla Managing Director

any

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Income statement for the 1st Quarter ended 31 March 2014 Unaudited

			Figures in '000'
	Note	Note 1st Quarter e	
		31 March 14	31 March 13
		Taka	Taka
Revenue	11	2,932,854	2,472,915
Cost of sales	12	(1,717,688)	(1,523,605)
Gross profit		1,215,166	949,310
Operating expenses	13	(867,705)	(704,965)
		347,461	244,345
Other income		12,368	12,562
		359,829	256,907
Financing cost		(84,773)	(67,762)
		275,056	189,145
Provision for contribution to WPPF		(13,753)	(9,457)
Profit before tax		261,303	179,688
Tax (expenses)/ income		(74,644)	(48,516)
Profit after tax		186,659	131,172
Earnings per share		6.52	4.59

til &

Dr. Arif Dowla Managing Director

in

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Statement of Comprehensive Income for the 1st Quarter ended 31 March 2014 Unaudited

	31 March 14 Taka	31 March 13 Taka
Net profit after tax for the period	186,659	131,172
Other comprehensive income:		
Change in fair value of available-for-sale financial assets	(3,730)	(22,044)
Income tax on other comprehensive income	373	2,204
Total other comprehensive income for the period, net of tax	(3,357)	(19,839)
Total comprehensive income for the period	183,302	111,332

til &

Dr. Arif Dowla Managing Director

any

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Statement of changes in equity for the 1st Quarter ended 31 March 2014 Unaudited

<u>Particulars</u>	Share capital <u>Taka</u>	Share premium <u>Taka</u>	Capital reserve <u>Taka</u>	Revaluation surplus <u>Taka</u>	Available for sare reserve <u>Taka</u>	Retained earnings <u>Taka</u>	Total <u>Taka</u>
Balance at 31 December 2012	237,738	321,893	1,671	894,622	140,860	3,484,502	5,081,286
Conversion of bonds into equity shares	446						446
Premium from conversion of bonds into shares	-	11,410	-	-	-	-	11,410
Changes in fair value for available for sale assets	-	-	-	-	(19,839)	-	(19,839)
Net profit after tax for the period ended 31 March 2013	-	-	-	-	-	131,172	131,172
Balance at 31 March 2013	238,184	333,303	1,671	894,622	121,021	3,615,674	5,204,475
Balance at 31 December 2013	285,821	333,302	1,671	892,464	111,330	4,012,664	5,637,252
Conversion of bonds into equity shares	797	-	-	-	-	-	797
Premium from conversion of bonds into shares	-	17,929	-	-	-	-	17,929
Changes in fair value for available for sale assets	-	-	-	-	(3,357)	-	(3,357)
Net profit after tax for the period ended 31 March 2014	-	-	-	-	-	186,659	186,659
Balance at 31 March 2014	286,618	351,231	1,671	892,464	107,973	4,199,323	5,839,280

til De

Dr. Arif Dowla Managing Director

amp

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Statement of Cash Flows for the 1st Quarter ended 31 March 2014

Unaudited

Unaudited				
		Figures in '000'		
	1st Quarte	er ended on		
	31 March 14	31 March 13		
	Taka	Taka		
A. Cash flows from operating activities				
Cash receipts from customers	2,960,031	2,364,497		
Cash receipts from other income	12,368	12,436		
Receipts from / (paid) to others	34,395	(44,604)		
	3,006,794	2,332,329		
Cash paid for:				
Purchase of inventory	(1,641,876)	(1,456,104)		
Operating expenses	(698,899)	(663,897)		
Payments to other payables	35,741	9,651		
Payments for advances, deposits and prepayments	(106,409)	(71,705)		
Paid to workers from WPPF	(1,302)	(2,291)		
Cash generated from operating activities	(2,412,745)	(2,184,346)		
Financing cost	(79,357)	(63,005)		
Income tax	(57,689)	(43,789)		
	(137,046)	(106,794)		
Net cash from operating activities	457,003	41,189		
B. Cash flows from investing activities	<u>_</u>			
Purchases of fixed assets	(7,300)	(65,876)		
Proceeds from sale of fixed assets	(7,500)	(03,070) 1,296		
	- (30,138)	(99,739)		
Payments for capital work-in-progress Investments in shares	(30, 130)	. ,		
	- (27,429)	(21,945)		
Net cash used in investing activities	(37,438)	(186,265)		
C. Cash flows from financing activities				
Inter-company receivables/ payables (paid)/ received	(218,116)	94,462		
Dividend paid	(128)	(330)		
Payment for finance lease	(209)	(180)		
Payment for redemption of Zero Coupon Bonds	(238,255)	(233,970)		
Short term bank loan (paid)/ received	97,071	401,607		
Long term bank loan (paid)/received	(13,957)	23,217		
Net cash used in financing activities	(373,594)	284,806		
D. Net cash inflows/(outflows) from total activities (A+B+C)	45,971	139,731		
E. Opening cash and bank balances	(357,240)	(1,212,636)		
F. Closing cash and bank balances (D+E)	(311,269)	(1,072,905)		
Closing balance represents:				
Cash and bank	303,351	132,243		
Bank overdraft	(614,620)	(1,205,148)		
	(311,269)	(1,072,905)		
til Del	Qui	7		
Dr. Arif Dowla	Pradin Kar Cho	/		

mar

Dr. Arif Dowla **Managing Director**

Pradip Kar Chowdhury **Chief Financial Officer**

Advanced Chemical Industries Limited Consolidated Statement of Financial Position As at 31 March 2014 Unaudited

	Unaudited		Figures in '000'
	Note	31-Mar-2014	31-Dec-2013
Non- current assets:		Taka	Taka
Property, plant and equipment			
At Cost / revaluation		8,931,739	8,818,556
Accumulated depreciation		(1,999,314)	(1,864,121)
	2(a)	6,932,425	6,954,435
Capital work-in-progress		801,075	761,927
nvestment		773,012	766,291
Biological assets		5,395	-
ntangible assets		85,904	74,435
otal non-current assets		8,597,811	8,557,088
Current assets:			
nventories	4(a)	5,251,471	5,388,657
rade receivables	5(a)	3,888,296	3,742,237
Other receivables	2()	150,213	172,001
Advance, deposits & prepayments	6(a)	922,422	712,316
Advance income tax	7(a)	894,501	793,072
nter-company receivables Cash and bank balance	7(a)	15,654 599,402	18,325 667,974
		11,721,959	11,494,582
otal assets		20,319,770	20,051,670
quity and liabilities:			
Share holders' equity			
Share capital		286,618	285,821
hare premium		351,232	333,302
Capital reserve		1,671	1,671
Revaluation surplus		1,511,620	1,511,620
vailable for sale reserve		107,973	111,330
Retained profit		1,593,855	1,548,581
Alia - 14 - 10 - 4 - 4		3,852,969	3,792,325
linority interest		239,508 	248,088 4,040,413
		4,092,477	4,040,413
Current liabilities Bank overdraft		967,287	1,024,270
Short term bank loan		7,869,977	7,996,384
ong-term loan-current portion		1,062,544	1,084,140
rade payables		1,363,805	1,262,616
Other payables	8(a)	1,724,114	1,447,364
Current portion of lease obligation		12,320	11,639
Current tax liability		1,008,429	872,346
		14,008,476	13,698,759
ong term liabilities	10(a)	2,218,817	2,312,498
otal equity and liabilities		20,319,770	20,051,670
til DI		(Int

the De

Dr. Arif Dowla **Managing Director**

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited

Consolidated Income Statement

for the 1st Quarter ended 31 March 2014

Unaudited

			Figures in '000'
		1st quar	ter ended on
	Note	31- March-14	31- March-13
		Taka	Taka
Revenue	11(a)	5,924,664	5,450,734
Cost of sales	12(a)	(4,038,331)	(3,889,344)
Gross profit		1,886,333	1,561,390
Other income		26,837	25,653
		1,913,170	1,587,043
Operating expenses	13(a)	(1,385,543)	(1,133,215)
		527,627	453,828
Profit/ (loss) from Associates and Joint	Ventures	5,750	8,841
		533,377	462,669
Financing cost		(357,311)	(332,286)
		176,066	130,383
Provision for contribution to WPPF		(21,770)	(16,968)
Profit before tax		154,296	113,415
Tax expenses		(129,468)	(105,164)
Profit after tax		24,828	8,251
Non-controlling interest		20,446	13,688
Profit after tax and minority interest		45,274	21,939
Basic earnings per share (EPS)		1.58	0.77

til &

Dr. Arif Dowla Managing Director

any

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Consolidated Statement of Comprehensive Income for the period ended 31 March 2014 Unaudited

	31- March-14 Taka	31- March-13 Taka
Net profit after tax for the period	24,828	8,251
Other comprehensive income:		
Change in fair value of available-for-sale financial assets	(3,730)	(22,044)
Income tax on other comprehensive income	373	2,204
Total other comprehensive income for the period, net of tax	(3,357)	(19,840)
Total comprehensive income for the period	21,471	(11,589)
Profit attributable to:		
Equity holders of the Company	41,917	2,099
Non-controlling interest	(20,446)	(13,688)
Total comprehensive income	21,471	(11,589)

til &

Dr. Arif Dowla Managing Director

amy

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Consolidated Statement of Changes in Equity for the 1st Quarter ended 31 March 2014 Unaudited

							Figures in '000'	
Particulars	Share capital Taka	Share premium Taka	Capital reserve Taka	Revaluation surplus Taka	Available for sale reserve Taka	Retained earnings Taka	Non-controlling interest Taka	Total Taka
Balance at 31 December 2012	237,738	321,893	1,671	1,513,778	140,860	1,580,925	358,514	4,155,379
Conversion of bonds into equity shares	446	-	-	-	-	-	-	446
Premium from conversion of bonds into shares	-	11,410	-	-	-	-	-	11,410
Changes in fair value for available for sale assets	-	-	-	-	(19,839)	-	-	(19,839)
Net profit after tax for the period ended 31 March 2013	-	-	-	-	-	21,939	(13,688)	8,251
Equity paid by non-controlling interest	-	-	-	-	-	-	7,000	7,000
Balance at 31 March 2013	238,184	333,303	1,671	1,513,778	121,021	1,602,864	351,826	4,162,646
Balance at 31 December 2013	285,821	333,302	1,671	1,511,620	111,330	1,548,581	248,088	4,040,413
Non-controlling interest at acquisition date						-	(294)	(294)
Conversion of bonds into equity shares	797	-	-	-	-	-	-	797
Premium from conversion of bonds into shares	-	17,930	-	-	-	-	-	17,930
Changes in fair value for available for sale assets	-	-	-	-	(3,357)	-	-	(3,357)
Net profit after tax for the period ended 31 March 2014	-	-	-	-	-	45,274	(20,446)	24,828
Equity paid by non-controlling interest	-	-	-	-	-	-	12,160	12,160
Balance at 31 March 2014	286,618	351,232	1,671	1,511,620	107,973	1,593,855	239,508	4,092,477

til &

Dr. Arif Dowla Managing Director

any

Pradip Kar Chowdhury Chief Financial Officer

Advanced Chemical Industries Limited Consolidated Statement of Cash Flows for the 1st Quarter ended 31 March 2014 Unaudited

		1st Quarter er		
		31 March 14	31 March 13	
		Taka	Taka	
Α	Cash flows from operating activities:	E 607 045	E 170 001	
	Cash receipts from customers	5,697,945	5,179,031	
	Cash receipts as other income	26,837	20,526	
	Receipts from / (payments to) others	32,037	(45,526)	
	Cosh poid for:	5,756,819	5,154,031	
	Cash paid for: Purchase of inventory	(3,663,450)	(3,687,809)	
	Operating expenses	(1,129,122)	(1,098,588)	
	Payments to other payables	31,126	14,761	
	Payments for advances, deposits and prepayments Paid to workers from WPPF	(203,931)	(56,266)	
		(4,892)	(2,291)	
	Cash generated from operating activities	(4,970,269)	(4,830,193)	
	Financing cost	(350,698)	(325,642)	
	Tax paid	(102,549)	(73,136)	
		(453,247)	(398,778)	
	Net cash provided by operating activities	333,303	(74,939)	
в	Cash flows from investing activities :			
	Purchase of fixed assets	(73,019)	(81,818)	
	Proceeds from sale of fixed assets		1,296	
	Payments for capital work-in-progress	(49,218)	(113,743)	
	Investments in shares/FDR	(13,569)	(1,886)	
	Net cash used in investing activities	(135,806)	(196,151)	
С	Cash flows from financing activities :			
	Inter-company receivables / payables- received/(paid)	2,671	(177)	
	Paid by non-controlling interest for shares	(9)	7,000	
	Dividend paid	(128)	(400)	
	Payment for finance lease	(2,730)	(2,322)	
	Payment for redemption of Zero Coupon Bonds	(238,255)	(233,970)	
	Short term bank loan received/(paid)	(126,407)	344,795	
	Long term bank loan (paid)/received	155,792 [′]	(76,045)	
	Net cash flows from financing activities	(209,066)	38,881	
D	Net cash inflows/(outflows) from total activities (A+B+C)	(11,569)	(232,209)	
Ē	Opening cash and bank balances	(356,316)	(836,079)	
F	Closing cash and bank balances (D+E)	(367,885)	(1,068,289)	
	Cash in hand and at bank	599,402	420,888	
	Bank overdraft	(967,287)	(1,489,178)	
		(367,885)	(1,068,289)	
	5 4 9 4	\bigcap		

til &

Dr. Arif Dowla Managing Director

Comp Pradip Kar Chowdhury

Chief Financial Officer

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 31 December 2013. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

3,423,342 84,109	2,975,420
- (682,684) 2,824,767	833,337 (385,415) (624,110) 2,799,232
8,818,556 113,183 - (1,999,314) 6,932,425	7,825,815 1,433,207 (440,466) (1,864,121) 6,954,435
1,226,019 460,453 151,425 4,665 1,842,562	1,226,019 460,453 155,155 4,665 1,846,292
1,823,269 66,169 518,301 206,896 30,611 <u>117,262</u> 2,762,508 183,051 2,579,457	1,774,219 56,751 502,928 169,566 30,789 <u>198,110</u> 2,732,363 179,032 2,553,331
3,558,957 96,883 1,256,006 318,394 78,061 229,157 5,537,458 285,987	3,546,220 96,764 1,316,958 272,375 109,409 318,478 5,660,204 271,547 5,388,657
	(682,684) 2,824,767 8,818,556 113,183 (1,999,314) 6,932,425 1,226,019 460,453 151,425 4,665 1,842,562 1,842,562 1,842,562 1,823,269 66,169 518,301 206,896 30,611 117,262 2,762,508 183,051 2,579,457 3,558,957 96,883 1,256,006 318,394 78,061 229,157 5,537,458

		31-Mar-14 Taka	Figures in '000' 31-Dec-13 Taka
5	Trade receivables		
	Debts due over six months Debts due below six months	339,730 1,282,620	307,263 1,340,475
	Less: Provision for doubtful debts	1,622,350 76,062	1,647,738 71,169
5 (0)	Consolidated trade receivables	<u> </u>	1,576,569
5 (a)			
	Debts due over six months Debts due below six months	792,393 3,290,023	1,699,640 2,228,004
	Less: Provision for doubtful debts	4,082,416 194,120 3,888,296	3,927,644 185,407 3,742,237
6	Advances, deposits & prepayments		
	Loan and advance to staff and others VAT current account. Advance for capital expenditure Deposits Prepayments	313,321 60,158 61,549 28,851 17,252 481,131	220,135 57,055 59,551 34,128 750 371,619
6 (a)	Consolidated advances, deposits & prepayments		
	Loan and advance to staff and others VAT current account. Advance for capital expenditure Deposits Prepayments	600,191 67,341 124,394 85,907 44,589 922,422	434,203 61,472 96,997 94,508 25,136 712,316
7	Inter-company receivables		
	Flyban Insecticides Limited Apex Leathercraft Limited Computer Technology Limited Tetley ACI (Bangladesh) Limited Asian Consumer Care (Pvt.) Limited ACI Salt Limited ACI Godrej Agrovet (Pvt.) Limited ACI Foods Limited ACI Foods Limited ACI Agrochemicals Limited Stochastic Logic Limited ACI Motors Limited Creative Communication ACI Pure Flour Limited ACI Logistics Limited ACI HealthCare Limited	1,014 98,198 30 535 8,184 375,843 880 662,934 229 6,025 252,230 - - - 28,088 2,868,194 80,364 4,382,748	1,014 99,543 30 442 8,205 354,572 880 746,527 229 8,768 210,565 39,370 10,724 44,535 2,508,801 42,891 4,077,096

	31-Mar-14 Taka	Figures in '000' 31-Dec-13 Taka
7 (a) Consolidated inter-company receivables		
Tetley ACI (Bangladesh) Limited Asian Consumer Care (PVT.) Limited	535 8,184	442 8,205
Computer Technology Limited	30	30
ACI Godrej Agrovet (Pvt.) Limited	880	880
Stochastic Logic Limited	6,025	8,768
	15,654	18,325
8 Other payables		
Creditors for expenses	512,256	359,756
Security money received from customers	224,175	205,395
Workers' profit participation fund	249,548	231,681
Unclaimed dividend	44,643	44,771
Tax deducted at source	23,437 126,016	21,597 122,826
Employees welfare fund Rights share deposit to be refunded	564	564
Family day fund	3,992	4,107
Unclaimed refund warrant-Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	26,664	13,811
Provident fund	8,646	6,628
Advertisement and promotional fund	279	3,104
	1,223,867	1,017,887
8 (a) Consolidated other payables		
Creditors for expenses	837,911	657,641
Security money received from customers	298,848	252,784
Workers' profit participation fund	314,484	295,109
Unpaid dividend	46,615	46,825
Provident fund	8,646	6,629
Tax deducted from suppliers and employees	47,649	31,518
Employees savings fund	126,016	122,826
Rights share deposit to be refunded Family day fund	564 3,992	563 4,107
Unclaimed refund warrant-Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	26,664	13,811
Creditors for capital expenditure	8,799	8,800
Advertisement and promotional fund	279	3,104
	1,724,114	1,447,364
9 Inter-company payables		
ACI Formulations Limited	444,304	363,251
	17,853	-
Creative Communication Limited		
Creative Communication Limited ACI Motors Limited	16,907	-
Creative Communication Limited		- 820 364,071

	31-Mar-14 Taka	Figures in '000' 31-Dec-13 Taka
10 Long term liabilities		
Staff gratuity provision	290,530	278,793
Other long term employee benefits	63,957	61,872
Deferred tax liabilities	86,640	94,712
Employees group insurance fund	400	400
Obligation under finance lease-due more than one year	1,893	2,137
Long term bank loan	249,739	275,501
ACI 20% Convertible Zero Coupon Bonds (ZCB)	693,159	241,751 955,166
	093,139	955,100
10 (a) Consolidated long term liabilities		
Staff gratuity provision	299,520	287,420
Other long term employee benefits	67,767	65,682
Deferred tax liabilities	304,829	316,345
Employees group insurance fund	400	400
Obligation under finance lease	19,195	22,129
Long term bank loan	1,527,106	1,378,771
ACI 20% Convertible Zero Coupon Bonds (ZCB)	-	241,751
	2,218,817	2,312,498
		Figures in '000'
	31-Mar-14	31-Mar-13
	Taka	Taka
11 Revenue	Taka	Taka
11 Revenue Pharmaceuticals	Taka 1,381,799	Taka 1,144,506
Pharmaceuticals	1,381,799	1,144,506
Pharmaceuticals Animal Health	1,381,799 412,369 894,381 13,738	1,144,506 300,167 867,324 15,729
Pharmaceuticals Animal Health Consumer brands	1,381,799 412,369 894,381 13,738 131,666	1,144,506 300,167 867,324 15,729 124,671
Pharmaceuticals Animal Health Consumer brands Seeds	1,381,799 412,369 894,381 13,738 131,666 98,901	1,144,506 300,167 867,324 15,729 124,671 20,518
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer	1,381,799 412,369 894,381 13,738 131,666	1,144,506 300,167 867,324 15,729 124,671
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer	1,381,799 412,369 894,381 13,738 131,666 98,901	1,144,506 300,167 867,324 15,729 124,671 20,518
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue	1,381,799 412,369 894,381 13,738 131,666 <u>98,901</u> 2,932,854	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue	1,381,799 412,369 894,381 13,738 131,666 <u>98,901</u> 2,932,854	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707)	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282)
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales 12 Cost of sales Opening stock	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116 1,647,379	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134 1,275,431
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales 12 Cost of sales Opening stock Purchase	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116 1,647,379 4,138,495	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134 1,275,431 3,376,565
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales 12 Cost of sales Opening stock	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116 1,647,379 4,138,495 (2,614,636)	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134 1,275,431 3,376,565 (2,014,146)
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales 12 Cost of sales Qpening stock Purchase Closing stock	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116 1,647,379 4,138,495 (2,614,636) 1,523,859	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134 1,275,431 3,376,565 (2,014,146) 1,362,419
Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Cropex 11 (a) Consolidated revenue Gross sales Inter-company sales Net sales 12 Cost of sales Opening stock Purchase	1,381,799 412,369 894,381 13,738 131,666 98,901 2,932,854 6,357,371 (432,707) 5,924,664 2,491,116 1,647,379 4,138,495 (2,614,636)	1,144,506 300,167 867,324 15,729 124,671 20,518 2,472,915 5,833,016 (382,282) 5,450,734 2,101,134 1,275,431 3,376,565 (2,014,146)

	31-Mar-14 Taka	Figures in '000' 31-Mar-13 Taka
12 (a) Consolidated cost of sales		
Opening stock Purchase	4,095,104 3,551,888	3,483,642 3,363,903
Closing stock	7,646,992 (3,979,433) 3,667,559	6,847,545 (3,280,857) 3,566,688
Manufacturing expenses	370,772 4,038,331	322,656 3,889,344
13 Operating expenses		
Administrative expenses Distribution expenses Selling expenses	79,567 101,701 <u>686,437</u> <u>867,705</u>	60,430 90,178 554,357 704,965
13 (a) Consolidated operating expenses		
Administrative expenses Distribution expenses Selling expenses	190,677 159,546 1,035,320 1,385,543	155,853 172,986 804,376 1,133,215

14 Consolidated operating segments

Please see at the next page

15 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

2

Dr. Arif Dowla Managing Director

amp

Pradip Kar Chowdhury Chief Financial Officer

Consolidated operating segments-1st Quarter 2014

	Reportable segment										Non-	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer brands	Crop Care and Public Health	ACI Motors	ACI Pure Flour	Retail chain	ACI Salt	ACI Foods	Premiaflex	reportable segment	adjustment	Total
	Taka	Taka	<u>Taka</u>	<u>Taka</u>	Taka	<u>Taka</u>	Taka	<u>Taka</u>	<u>Taka</u>	<u>Taka</u>	<u>Taka</u>	<u>Taka</u>	Taka
External revenue	1,381,799	412,369	894,381	448,860	337,596	626,350	762,474	319,880	150,408	322,574	267,974	-	5,924,664
Inter-segment revenue	-	-	-	-	-	3,373	-	1,916	20,550	50,609	356,259	(432,707)	-
Finance cost	37,665	7,485	29,345	11,705	1,148	4,807	154,728	29,588	41,394	26,061	13,383	-	357,311
Operating expenses	492,871	87,917	217,971	81,696	66,018	38,965	199,659	59,196	40,433	10,067	92,349	(1,601)	1,385,543
Depreciation and amortisation	44,110	4,387	8,829	5,514	115	5,923	23,577	19,404	4,324	10,487	2,348	6,175	135,193
Segment profit before tax	238,479	37,339	32,033	85,937	21,543	19,386	(247,607)	3,103	(44,024)	31,700	(32,618)	9,024	154,296
Segment assets	3,911,569	1,121,306	2,759,894	1,710,200	1,475,348	723,064	2,078,857	1,366,583	371,410	1,452,770	1,999,297	1,349,472	20,319,770
Segment external liabilities	1,251,725	502,355	966,910	489,823	1,240,159	485,091	5,415,856	1,133,407	1,306,441	1,014,399	806,442	1,614,684	16,227,293

Consolidated operating segments-1st Quarter 2013

		Reportable segment											
Particulars	Pharmaceuticals	Animal Health	Consumer brands	Crop Care and Public Health	ACI Motors	ACI Pure Flour	Retail chain	ACI Salt	ACI Foods	Premiaflex	reportable segment	Unallocated/ adjustment	Total
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
External revenue	1,144,506	300,167	867,324	403,368	255,920	701,347	837,129	296,131	149,663	318,509	176,668	-	5,450,734
Inter-segment revenue	-	-	-	-	-	4,048	-	3,594	10,448	40,422	323,772	(382,283)	-
Finance cost	30,107	5,983	23,567	21,567	9,029	11,879	123,887	30,210	36,801	28,038	11,217	-	332,286
Operating expenses	415,510	63,429	178,935	77,254	40,852	32,391	183,141	42,617	33,333	7,740	60,491	(2,478)	1,133,215
Depreciation and amortisation	37,277	4,205	8,404	5,688	345	6,485	22,538	19,178	4,444	10,416	2,062	6,190	127,231
Segment profit before tax	162,260	25,276	26,501	72,950	12,031	20,145	(201,512)	16,629	(37,223)	21,956	(21,683)	16,085	113,415
Segment assets	4,257,996	806,978	2,068,940	1,831,615	1,267,599	844,020	1,500,262	1,352,139	339,891	1,295,846	1,187,334	1,391,089	18,143,708
Segment liabilities	1,035,321	266,678	758,552	286,966	1,123,103	697,411	3,954,582	1,137,560	1,106,916	934,368	294,811	2,384,791	13,981,061

Note-14